OLS : Record


Main Title Antibody-Drug Conjugates The 21st Century Magic Bullets for Cancer / [electronic resource] :
Publisher Springer International Publishing : Imprint: Springer,
Place Published Cham
Year Published 2015
Subject Added Ent Medicine.; Pharmaceutical technology.
Internet Access
Description Access URL
Library   Call Number Additional Info Location Date Modified
Collation X, 252 p. 59 illus., 32 illus. in color. online resource.
Contents Notes 1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions. This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
Author Added Ent
Wang, Jeffrey.;
Shen, Wei-Chiang.;
Zaro, Jennica L.
Corporate Au Added Ent SpringerLink (Online service)
Title Ser Add Ent AAPS Advances in the Pharmaceutical Sciences Series, 17
Host Item Entry Springer eBooks
PUB Date Free Form 2015
Series Title Untraced AAPS Advances in the Pharmaceutical Sciences Series, 17
BIB Level m
Medium computer
ISBN 9783319130811
OCLC Time Stamp 20150519192005
Cataloging Source OCLC/T
Language eng
OCLC Rec Leader 03878nam a22004575i 45